In addition, in clinical practice, the regimen of taxane, carboplatin, and trastuzumab in combination with pertuzumab (TCbHP) has become the preferred and the most commonly used neoadjuvant regimens for HER2 + BrCa in China [13]. Here, ERBB2 is linked to invasive breast carcinoma.